

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

FEB 28 2002

Page 1 of 1

FORM PTO-449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	SERIAL NO. TECH CENTER 1600/2902 09/98,507	ATTORNEY DOCKET NO. 3302.2.1
	FILING DATE November 28, 2001	GROUP ART UNIT
	APPLICANT(S): Laixin Wang	


REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
PS	A1	20,010,005,717	06/28/2001	Wagner		04/17/2000


NON-PATENT DOCUMENTS

PS	A2	Akhtar, Saghir, et al. "The Delivery of Antisense Therapeutics," Advanced Drug Delivery Reviews 44, (2000), 3-21
	A3	Akiyama, Yoshitsugu, et al., "Synthesis of Poly(ethylene glycol)-block-poly(ethylenimine) Possessing an Acetal Group at the PEG End," Macromolecules, 2000, 33, 5841-45.
	A4	Abdallah, Bassima, et al., "A Powerful Nonviral Vector for In Vivo Gene Transfer Into the Adult Mammalian Brain: Polyethylenimine," Human Gene Therapy 7, 1947-54, October 20, 1996
	A5	Bandyopadhyay, Paramita, et al., "Enhanced Gene Transfer into HuH-7 Cells and Primary Rat Hepatocytes Using Targeted Liposomes and Polyethylenimine," BioTechniques 25: 282-292, August, 1998
	A6	Bettinger, Thierry, et al, "Size Reduction of Galactosylated PEI/DNA Complexes Improves Lectin-Mediated Gene Transfer into Hepatocytes," Bioconjugate Chemistry, 1999, 10, 558-561
	A7	Bieber, Thorsten, et al., "Preparation of Low Molecular Weight Polyethylenimine for Efficient Cell Transfection," BioTechniques 30: 74-81 (January, 2001)
	A8	Blessing, Thomas, "Different Strategies for Formation of PEGylated EGF-Conjugated PEI/DNA Complexes for Targeted Gene Delivery," Bioconjugate Chemistry 2001, 12, 529-37
	A9	Boussif, Otmane, et al, "A Versatile Vector for Gene and Oligonucleotide Transfer Into Cells In Culture and In Vivo: Polyethylenimine," Proc. Nat'l. Acad. Sci. USA, vol. 92, 7297-7301, August, 1995
PS	A10	Bronich, Tatiana K., et al., "Self-assembly in Mixtures of Poly(ethylene oxide)-graft-Poly(ethyleneimine) and Alkyl Sulfates, Langmuir, 1998, 14, 6101-106

EXAMINER 	DATE CONSIDERED 2/2/04
--	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

BEST AVAILABLE COPY



COPY OF PAPERS
ORIGINALLY FILED

Page 2 of 2


RS	A11	Coll, Jean-Luc, et al., "In Vivo Delivery to Tumors of DNA Complexed with Linear Polyethylenimine," Human Gene Therapy, 10, 1659-66, July 1, 1999
	A12	De Smedt, Steffan C., et al., "Cationic Polymer Based Gene Delivery System," Pharmaceutical Research, Vol. 17, No. 2, 2000, 113-126
	A13	Dheur, Sonia, et al., "Polyethylenimine but Not Cationic Lipid Improves Antisense Activity of 3'-Capped Phosphodiester Oligonucleotides," Antisense & Nucleic Acid Drug Development, 9:515-525 (1999)
	A14	Diebold, Sandra S., et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells," The Journal of Biological Chemistry, Vol. 274, No. 27, July 2, 1999, 19087-94
	A15	Fischer, Dagmar, et al., "A Novel Non-Viral Vector for DNA Delivery Based on Low Molecular Weight, Branched Polyethylenimine: Effect of Molecular Weight on Transfection Efficiency and Cytotoxicity," Pharmaceutical Research, Vol. 16, No. 8, 1999
	A16	Godbey, W.T., et al., "Poly(ethylenimine)-mediated transfection. A new paradigm for Gene Delivery," 321-28, BioMed Mater Res., June, 2000
	A17	Godbey, W.T., et al., "Size matters: Molecular Weight Affects the Efficiency of poly(ethylenimine as a Gene Delivery Vehicle," BioMed Mater Res., June, 1999, 5:45(3), 268-75
	A18	Godbey, W.T., et al., "Recent Progress In Gene Delivery Using Non-Viral Transfer Complexes," Journal of Controlled Release 72, 2001, 115-25
	A19	Godbey, W.T., et al., "Poly(ethylenimine) and its Role in Gene Delivery," Journal of Controlled Release, 60, (1999) 149-160
	A20	Goula, D., et al., "Rapid Crossing of The Pulmonary Endothelial Barrier By Polyethylenimine/DNA Complexes," Gene Therapy 2000, 7, 499-504
	A21	Han, Sang-oh, et al., "Water-Soluble Lipopolymer for Gene Delivery," Bioconjugate Chemistry, 2001, 12, 337-345
	A22	Kircheis, Ralf, et al., "Design and Gene Delivery Activity of Modified Polyethylenimines," Advanced Drug Delivery Reviews, Vol. 53, Issue 3, December 31, 2001, 341-358
	A23	Kircheis, Ralf, et al., "Tumor Targeting with Surface-Shielded Ligan-Polycation DNA Complexes," Journal of Controlled Release, 72, 2001, 165-170
	A24	Liu, Feng, et al., "Glucose-Induced Release of Glycosylpoly(ethylene-glycol) Insulin Bound to a Soluble Conjugate of Concanavalin A," Bioconjugate Chem. 1997, 8, 664-72
	A25	Nguyen, H-K, et al., "Evaluation of Polyether-polyethyleneimine Graft Copolymers as Gene Transfer Agents," Gene Therapy 2000, 7, 126-138
RS	A26	Park, Y.K., et al., "Galatosylated Chitosan-Graft-Dextran as Hepatocyte-Targeting DNA Carrier," Journal of Controlled Release, 69, 2000, 97-108

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

BEST AVAILABLE COPY



COPY OF PAPERS
ORIGINALLY FILED


Page 3 of 3

<i>Rs</i>	A27	Pouton, Colin W., et al., "Key Issues in Non-Viral Gene Delivery," Advanced Drug Delivery Reviews 46 (2001) 187-203
	A28	Robaczewka, M., et al., "Inhibition of Hepadnaviral Replication By Polyethylenimine-based Intravenous Delivery of Antisense Phosphodiester Oligodeoxynucleotides to the Liver," Gene Therapy, 2001, 8, 874-881
	A29	Vinogradov, Serguei V., et al., "Self-Assembly of Polyamine-Poly(ethylene glycol) Copolymers with Phosphorothioate Oligonucleotides," Bioconjugate Chem., 1996, 9, 805-812
	A30	Wagner, Ernst, "Application of Membrane-Active Peptides for Nonviral Gene Delivery," Advanced Drug Delivery Reviews, 38, (1999) 279-289
<i>Rs</i>	A31	Yu, Lei, et al., "TerplexDNA Gene Carrier System Targeting Artery Wall Cells," Journal of Controlled Release, 72, (2001), 179-189

EXAMINER <i>RLG</i>	DATE CONSIDERED <i>2/2/04</i>
---------------------	-------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

BEST AVAILABLE COPY



PTO/SB/08A (05-03)
Approved for use through 5/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 1	Complete if Known	
	Application Number	09/996,507
	Filing Date	November 28, 2001
	First Named Inventor	Laixin Wang
	Group Art Unit	1635
	Examiner Name	
	Attorney Docket Number	3302.2.1

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (If known)			
ES	U1	US-6,440,743	08/27/2002	Kabanov et al.	
	U2	US-6,333,051	12/25/2001	Kabanov et al.	
	U3	US-6,312,727	11/06/2001	Schacht et al.	
	U4	US-6,300,317	10/09/2001	Szoka, Jr. et al.	
	U5	US-6,231,892	05/15/2001	Hubbell et al.	
	U6	US-6,153,597	11/28/2000	Blanche et al.	
	U7	US-6,113,946	09/05/2000	Szoka, Jr. et al.	
	U8	US-5,820,882	10/13/1998	Hubbell et al.	
	U9	US-5,661,025	08/26/1997	Szoka, Jr. et al.	
	U10	US-5,656,611	08/12/1997	Kabanov et al.	
	U11	US-5,389,381	02/14/1995	Phillips et al.	
	U12	US-5,380,536	01/10/1995	Hubbell et al.	
	U13	US-5,275,824	01/04/1994	Carti et al.	
	U14	US-5,256,652	10/26/1993	El-Rashidy	
R	U15	US-5,079,237	01/07/1992	Husu et al.	

Examiner Signature		Date Considered	2/2/04
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and selection option 2.

BEST AVAILABLE COPY